1.5-year post-treatment follow-up of radium-223 dichloride (Ra-223) in patients with castration-resistant prostate cancer (CRPC) and bone metastases from the phase 3 ALSYMPCA study.

Authors

Sten Nilsson

Karolinska University Hospital, Stockholm, Sweden

Sten Nilsson , Nicholas J. Vogelzang , A. Oliver Sartor , David Bottomley , Robert E. Coleman , Irene Skjorestad , Mona Wahba , Chris Parker

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2015 Genitourinary Cancers Symposium

bookmark_border

External beam radiation therapy (EBRT) use and safety with radium-223 dichloride (Ra-223) in patients (pts) with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases (mets) from the ALSYMPCA trial.

First Author: Steven E. Finkelstein

insert_chart_outlined

Poster

2013 ASCO Annual Meeting

bookmark_border

Hematologic safety of Ra-223 dichloride (Ra-223) in castration-resistant prostate cancer (CRPC) patients with bone metastases from the phase III ALSYMPCA trial.

First Author: Chris Parker

insert_chart_outlined

Poster

2018 Genitourinary Cancers Symposium

bookmark_border

Intergroup study EORTC-1333-GUCG: A randomized multicenter phase III trial comparing enzalutamide vs. a combination of Ra223 and enzalutamide in asymptomatic or mildly symptomatic castration resistant prostate cancer (CRPC) patients metastatic to bone (PEACE III).

First Author: Bertrand F. Tombal

insert_chart_outlined

Poster

2015 Genitourinary Cancers Symposium

bookmark_border

3-year safety follow-up of radium-223 dichloride (Ra-223) in patients (Pts) with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases (Mets) from ALSYMPCA.

First Author: Chris Parker